These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 17934363)
21. Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. Pruemer J Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S4-10. PubMed ID: 19139489 [TBL] [Abstract][Full Text] [Related]
22. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Glanz J; France E; Xu S; Hayes T; Hambidge S Pediatrics; 2008 Mar; 121(3):e506-12. PubMed ID: 18310170 [TBL] [Abstract][Full Text] [Related]
23. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649 [TBL] [Abstract][Full Text] [Related]
24. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Kojouri K; George JN Int J Hematol; 2005 Feb; 81(2):119-25. PubMed ID: 15765779 [TBL] [Abstract][Full Text] [Related]
26. [Clinical course, diagnostic and therapeutic management of immune thrombocytopenic purpura in children]. Mitura-Lesiak M; Filiks-Litwin B; Malek U; Kowalczyk JR Med Wieku Rozwoj; 2004; 8(4 Pt 1):1004-11. PubMed ID: 15951618 [TBL] [Abstract][Full Text] [Related]
27. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. De Mattia D; Del Vecchio GC; Russo G; De Santis A; Ramenghi U; Notarangelo L; Jankovic M; Molinari AC; Zecca M; Nobili B; Giordano P; Acta Haematol; 2010; 123(2):96-109. PubMed ID: 20029174 [TBL] [Abstract][Full Text] [Related]
28. Management of chronic immune thrombocytopenic purpura in children and adults. Blanchette V; Freedman J; Garvey B Semin Hematol; 1998 Jan; 35(1 Suppl 1):36-51. PubMed ID: 9523748 [TBL] [Abstract][Full Text] [Related]
29. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292 [TBL] [Abstract][Full Text] [Related]
30. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902 [TBL] [Abstract][Full Text] [Related]
32. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up. Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621 [TBL] [Abstract][Full Text] [Related]
34. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Neunert CE; Bright BC; Buchanan GR Pediatr Blood Cancer; 2008 Oct; 51(4):513-6. PubMed ID: 18506754 [TBL] [Abstract][Full Text] [Related]
35. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Schweizer C; Reu FJ; Ho AD; Hensel M Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529 [TBL] [Abstract][Full Text] [Related]
39. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Cooper N; Evangelista ML; Amadori S; Stasi R Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569 [TBL] [Abstract][Full Text] [Related]
40. [Idiopathic thrombocytopenic purpura in children]. Gebauer E; Vijatov G Med Pregl; 1998; 51(3-4):127-34. PubMed ID: 9611955 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]